Disciplined Execution,
Globally Delivered

Michael Zhang is the Founder & CEO of Luminark Holdings, with more than 35 years of experience in corporate operations, industrial resource integration, and U.S. capital markets project execution. He has long been deeply engaged in the electronics industry, global supply chains, professional service networks, healthcare-related services, and artificial intelligence infrastructure. He is skilled at building enterprise platforms with financing capability and expansion potential by systematically advancing opportunities from industrial opportunity assessment, project structure design, and team organization to capital markets pathway execution.

Since 2015, Michael has continuously participated in U.S. public market-related projects, with a focus on sponsor-side structure design, corporate governance, transaction preparation, and listed-platform development. His practical experience in cross-border capital markets project organization and public market execution spans the full lifecycle from sponsor formation through NYSE listing and post-close operations.

As the Founder and CEO of Luminark Holdings, Michael leads the company's systematic layout across direct investment, AI infrastructure, healthcare innovation, premium service networks, and future public market opportunities. He is committed to transforming early-stage opportunities with real industrial foundations into enterprise platforms that are governable, financeable, scalable, and capable of creating capital markets value.

Dr. Li Lu is a New York-based physician, healthcare entrepreneur, and founder of multi-location healthcare service platforms, with deep experience in clinical medicine, healthcare operations, physician-led care models, aesthetic medicine, integrative wellness, and holistic health.

She co-founded East Sunrise Medical Care and later became a shareholder of Rendr Medical Group, expanding her role across clinical care, healthcare operations, medical resource integration, and medical platform development. She is also the founder of LL Blossoms & Holistic Medicine, a multi-location clinical platform focused on aesthetic medicine, integrative wellness, holistic health, personalized care, and premium healthcare services.

At Luminark Holdings, Dr. Lu provides strategic guidance on healthcare strategy, physician-led care platforms, medical aesthetics, functional medicine, holistic health, clinical project evaluation, healthcare service innovation, and healthcare investment opportunities.

Andy Ou is a Nasdaq-listed company founder, public market entrepreneur, and strategic investor with deep experience in company building, capital market strategy, business scaling, and cross-sector venture development.

As the Founder and Chief Executive Officer of Fly-E Group, Inc., Andy led the company from its entrepreneurial stage to its listing on the Nasdaq Capital Market. His journey reflects a rare combination of founder-level execution, public company leadership, capital market discipline, and the ability to transform an operating business into a publicly traded enterprise.

Andy's experience gives him a practical and strategic understanding of how growth companies access the public markets, build scalable operating structures, communicate with investors, and navigate the transition from private enterprise to public company. His perspective is especially valuable for founders and growth-stage businesses seeking to connect operational expansion with capital market opportunities.

Beyond his leadership in the public markets, Andy continues to invest in and evaluate emerging business opportunities across technology-enabled companies, AI-driven service models, consumer platforms, food and beverage ventures, and scalable operating businesses. His investment judgment is grounded in real-world execution, market timing, operational discipline, and the ability to identify companies with long-term expansion potential.

At Luminark Holdings, Andy serves as Senior Strategic Advisor, Public Markets & Venture Growth, supporting the firm's evaluation of public market opportunities, growth-stage ventures, AI-enabled business models, consumer and service platforms, and business opportunities with strong potential for scale, growth, and long-term value creation.